Prognostic Analysis of Patients with Advanced Non-small Cell Lung Cancer 
in Different Genotypes

• Published in: Zhongguo fei ai za zhi Vol. 20; no. 11; pp. 741 - 750
• Main Authors: Liu, Ping, Wu, Yuhua, Zhou, Lijuan, Qin, Na, Zhang, Quan, Zhang, Hui, Li, Xi, Zhang, Xinyong, Lv, Jialin, Yang, Xinjie, Wang, Jinghui, Zhang, Shucai
• Format: Journal Article
• Language: Chinese
• Published: China Chinese Anti-Cancer Association Chinese Antituberculosis Association 20.11.2017; Chinese Anti-Cancer Association; Chinese Antituberculosis Association
• Subjects: Adult; Aged; Aged, 80 and over; Anaplastic lymphoma kinase; Cancer therapies; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - mortality; Carcinoma, Non-Small-Cell Lung - pathology; Chemotherapy; Disease-Free Survival; Epidermal growth factor; Epidermal growth factor receptor; Female; Genotype; Humans; Kinases; Lung cancer; Lung neoplasms; Lung Neoplasms - drug therapy; Lung Neoplasms - mortality; Lung Neoplasms - pathology; Lymphoma; Male; Middle Aged; Mutation; Mutation - genetics; Oncology; Prognosis; Protein Kinase Inhibitors - therapeutic use; Pyrazoles - therapeutic use; Pyridines - therapeutic use; Receptor Protein-Tyrosine Kinases - genetics; Receptor, Epidermal Growth Factor - genetics; Retrospective Studies; Survival analysis; Tumors; Beijing China; United States > US; Asia; China; Taiwan; Prognosis; Anaplastic lymphoma kinase; Epidermal growth factor receptor; Lung neoplasms
• ISSN: 1009-3419; 1999-6187
• DOI: 10.3779/j.issn.1009-3419.2017.11.04

Non-small cell lung cancer (NSCLC) has been transformed from the treatment according to histological type to genotype treatment model. The epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) genes are the most important drivers in lung cancer. The aim of this study is to explore the clinical characteristics and prognostic factors of patients with advanced NSCLC with different genotypes. We retrospectively reviewed the clinical data of 553 advanced NSCLC patients with EGFR mutations and ALK positive who were hospitalized in the Beijing Chest Hospital from July 2004 to December 2015, and the independent prognostic factors of patients were analyzed by Cox proportional hazards regression model. The clinical data of 553 patients (227 with EGFR mutations, 58 with ALK positive, 2 with EGFR and ALK co-mutation and 266 with wild-type) with advanced NSCLC were enrolled in this study. The median survival time of 227 patients with EGFR mutations was 28.7 mo (95%CI: 22.160-35.240), and the perform